正在研发的用于预防视神经脊髓炎复发的研究性药物。
Investigational drugs in development to prevent neuromyelitis optica relapses.
作者信息
Paul Friedemann, Murphy Olwen, Pardo Santiago, Levy Michael
机构信息
a Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, NeuroCure Clinical Research Center , Berlin , Germany.
b Experimental and Clinical Research Center , Max Delbrueck Center for Molecular Medicine Charité - Universitätsmedizin Berlin , Berlin , Germany.
出版信息
Expert Opin Investig Drugs. 2018 Mar;27(3):265-271. doi: 10.1080/13543784.2018.1443077. Epub 2018 Feb 28.
INTRODUCTION
In the short time since 2014, three pivotal, worldwide studies in neuromyelitis optica spectrum disorders have been launched: eculizumab, SA237 and inebelizumab, each based on a unique mechanism.
AREAS COVERED
In this review, we provide a discussion on the trial data available for each drug, a brief description of the trial design, and our expert opinion on the potential benefits and risks.
EXPERT OPINION
Eculizumab, a C5 complement inhibitor, may prove useful in the treatment of intractable cases of NMOSD, but physicians must be aware of the known risk of meningococcal infection. SA237, an interleukin-6 receptor blocker, may be effective at reducing relapse risk, and also has the potential to reduce neuropathic pain in NMOSD. Inebelizumab, a B cell depleting agent, has never been tested in NMOSD, but based on extensive evidence of efficacy with B cell depletion using rituximab, inebelizumab is expected to work at least as well.
引言
自2014年以来的短时间内，开展了三项针对视神经脊髓炎谱系障碍的关键全球性研究：依库珠单抗、SA237和inebelizumab，每项研究都基于独特的作用机制。
涵盖领域
在本综述中，我们讨论了每种药物的现有试验数据，简要描述了试验设计，并给出了我们关于潜在益处和风险的专家意见。
专家意见
依库珠单抗是一种C5补体抑制剂，可能在治疗难治性视神经脊髓炎谱系障碍病例中有用，但医生必须意识到已知的脑膜炎球菌感染风险。SA237是一种白细胞介素-6受体阻滞剂，可能在降低复发风险方面有效，并且也有降低视神经脊髓炎谱系障碍患者神经性疼痛的潜力。Inebelizumab是一种B细胞耗竭剂，从未在视神经脊髓炎谱系障碍中进行过测试，但基于使用利妥昔单抗进行B细胞耗竭的大量疗效证据，预计inebelizumab至少会有同样的效果。
Zotero 插件